Research Article
Prevalence and Associated Factors of Anemia among Breast Cancer Patients Undergoing Chemotherapy: A Prospective Study
Table 3
Association between prevalence of anemia and demographic and clinical factors.
| | Variable | Anemia | –valuea | | With Frequency of Anemia, n (%) | Without Frequency of Anemia, n (%) |
| | Age (years) | < 60 | 31 (19.5%) | 128 (80.5%) | 0.001 | | ≥ 60 | 89 (66.9%) | 44 (33.1%) | | BMI kg/m2 | Obese (≥25) | 100 (57.5%) | 74 (42.5%) | 0.002 | | Nonobese (<25) | 20 (16.9%) | 98 (83.1) | | Menopausal status | Pre | 56 (60.9%) | 36 (39.1%) | 0.001 | | Post | 64 (32%) | 136 (68%) | | Cancer stage | Stage I | 5 (22.7%) | 17 (77.3%) | 0.036 | | Stage II | 29 (35.8%) | 52 (54.2%) | | Stage III | 62 (50%) | 62 (50%) | | Stage IV | 24 (36.9%) | 41 (63.1%) | | Number of regimens | 1 | 93 (66%) | 48 (34%) | 0.001 | | > 1 | 27 (17.9%) | 124 (82.1%) | | Dose reduced | Reduced | 23 (45.1%) | 28 (54.9%) | 0.001 | | Not reduced | 66 (32.8%) | 138 (67.2%) | | Not detected | 31 (83.8%) | 6 (16.2%) | | Dose delay | Delayed | 62 (48.4%) | 66 (51.6%) | 0.024 | | Not delayed | 58 (35.4%) | 106 (64.6%) | | Docetaxel | Received | 45 (47%) | 34 (43%) | 0.001 | | Not received | 75 (35.2%) | 138 (64.8%) |
|
|
aChi-squared analysis. < 0.05 indicates a level of significance. Fisher exact test. < 0.05 indicates a level of significance. |
